About: Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer
Creator	Bank, Ilan Cabantous, Stéphanie Calvayrac, Olivier Favre, Gilles Figarol, Sarah Fournié, Jean-Jacques Laplagne, Chloé Laurent, Camille Meddour, Sarah Michelas, Marie Poupot, Mary Scotet, Emmanuel
Source	Medline; PMC
abstract	Vγ9Vδ2 T cells are known to be efficient anti-tumor effectors activated through phosphoantigens (PAg) that are naturally expressed by tumor cells or induced by amino bisphosphonates treatment. This PAg-activation which is TCR and butyrophilin BTN3A dependent can be modulated by NKG2D ligands, immune checkpoint ligands, adhesion molecules, and costimulatory molecules. This could explain the immune-resistance observed in certain clinical trials based on Vγ9Vδ2 T cells therapies. In NSCLC, encouraging responses were obtained with zoledronate administrations for 50% of patients. According to the in vivo results, we showed that the in vitro Vγ9Vδ2 T cell reactivity depends on the NSCLC cell line considered. If the PAg-pretreated KRAS mutated A549 is highly recognized and killed by Vγ9Vδ2 T cells, the EGFR mutated PC9 remains resistant to these killers despite a pre-treatment either with zoledronate or with exogenous BrHPP. The immune resistance of PC9 was shown not to be due to immune checkpoint ligands able to counterbalance NKG2D ligands or adhesion molecules such as ICAM-1 highly expressed by PC9. RHOB has been shown to be involved in the Vγ9Vδ2 TCR signaling against these NSCLC cell lines, in this study we therefore focused on its intracellular behavior. In comparison to a uniform distribution of RHOB in endosomes and at the plasma membrane in A549, the presence of large endosomal clusters of RHOB was visualized by a split-GFP system, suggesting that RHOB rerouting in the PC9 tumor cell could impair the reactivity of the immune response.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01396
bibo:pmid	32733462
has license	cc-by
sha1sum (hex)	cd8db4e6dea6a488df3edc8802a7f13bb0c7d371
schema:url	https://doi.org/10.3389/fimmu.2020.01396
resource representing a document's title	Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer
has PubMed Central identifier	PMC7358576
has PubMed identifier	32733462
schema:publication	Front Immunol
resource representing a document's body	covid:cd8db4e6dea6a488df3edc8802a7f13bb0c7d371#body_text
is schema:about of	named entity 'plasma membrane' named entity 'immune response' named entity 'naturally' named entity 'induced' named entity 'ICAM-1' named entity 'CERTAIN' named entity 'PAG' named entity 'TCR SIGNALING' named entity 'PRE' named entity 'RESULTS' named entity 'HIGHLY' named entity 'IN VIVO' named entity 'RESISTANCE' named entity 'COUNTERBALANCE' named entity 'GFP' named entity 'RHOB' named entity 'PHOSPHOANTIGENS' named entity 'ACTIVATION' named entity 'remains' named entity 'observed' named entity 'responses' named entity 'RHOB' named entity 'patients' named entity 'PAg' named entity 'reactivity' named entity 'This' named entity 'expressed' named entity 'KRAS' named entity 'TCR' named entity 'T cell' named entity 'endosomes' named entity 'anti-tumor' named entity 'T cells' named entity 'mutated' named entity 'NKG2D' named entity 'immune checkpoint' named entity 'recognized' named entity 'uniform distribution' named entity 'adhesion molecules' named entity 'effectors' named entity 'NKG2D' named entity 'T Cells' named entity 'endosomal' named entity 'RHOB' named entity 'uniform distribution' named entity 'ligands' named entity 'EGFR' named entity 'zoledronate' named entity 'ICAM-1' named entity 'endosomes' named entity 'GFP' named entity 'immune response' named entity 'RHOB' named entity 'system' named entity 'immune' named entity 'MVB' named entity 'LFA-1' named entity 'PBS buffer' named entity 'tumors' named entity 'cell lines' named entity 'RHOB' named entity 'co-culture' named entity 'plasma membrane' named entity 'EGFR' named entity 'mevalonate' named entity 'RHOB' named entity 'co-culture' named entity 'antitumor' named entity 'primary antibodies' named entity 'PBS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software